

PAPER

Pixel size limit of the PRIMA implants: from humans to rodents and back

To cite this article: Bing-Yi Wang *et al* 2022 *J. Neural Eng.* **19** 055003

View the [article online](#) for updates and enhancements.

You may also like

- [Decoding network-mediated retinal response to electrical stimulation: implications for fidelity of prosthetic vision](#)
Elton Ho, Alex Shmakov and Daniel Palanker
- [A binary readout chip for silicon microstrip detector in proton imaging application](#)
V. Sipala, M. Bruzzi, M. Bondi *et al.*
- [Advances in visual prostheses: engineering and biological challenges](#)
Eleonora Borda and Diego Ghezzi



EDINBURGH INSTRUMENTS

WORLD LEADING MOLECULAR SPECTROSCOPY SOLUTIONS

edinst.com

The advertisement features a red background with the Edinburgh Instruments logo on the left, which consists of a stylized sunburst of white dots. In the center and right, several pieces of laboratory equipment are displayed, including a large white spectrometer labeled 'FLS 1000' and a smaller instrument labeled 'FSS'. The text 'EDINBURGH INSTRUMENTS' is prominently displayed in white, bold, uppercase letters. Below the logo, the text 'WORLD LEADING MOLECULAR SPECTROSCOPY SOLUTIONS' is written in white, bold, uppercase letters. In the bottom right corner, the website 'edinst.com' is shown in white text on a red rectangular background.



PAPER

Pixel size limit of the PRIMA implants: from humans to rodents and back

Bing-Yi Wang^{1,*} , Zhijie Charles Chen² , Mohajeet Bhuckory^{3,4} , Anna Kochnev Goldstein² and Daniel Palanker^{3,4} ¹ Department of Physics, Stanford University, Stanford, CA, United States of America² Department of Electrical Engineering, Stanford University, Stanford, CA, United States of America³ Department of Ophthalmology, Stanford University, Stanford, CA, United States of America⁴ Hansen Experimental Physics Laboratory, Stanford University, Stanford, CA, United States of America

* Author to whom any correspondence should be addressed.

E-mail: bingyiw@stanford.edu**Keywords:** retinal prosthesis, restoration of sight, neural stimulation, electrophysiology, photovoltaicRECEIVED
4 July 2022REVISED
17 August 2022ACCEPTED FOR PUBLICATION
31 August 2022PUBLISHED
13 September 2022**Abstract**

Objective. Retinal prostheses aim at restoring sight in patients with retinal degeneration by electrically stimulating the inner retinal neurons. Clinical trials with patients blinded by atrophic age-related macular degeneration using the PRIMA subretinal implant, a 2×2 mm array of 100 μm -wide photovoltaic pixels, have demonstrated a prosthetic visual acuity closely matching the pixel size. Further improvement in resolution requires smaller pixels, which, with the current bipolar design, necessitates more intense stimulation. *Approach.* We examine the lower limit of the pixel size for PRIMA implants by modeling the electric field, leveraging the clinical benchmarks, and using animal data to assess the stimulation strength and contrast of various patterns. Visually evoked potentials measured in Royal College of Surgeons rats with photovoltaic implants composed of 100 μm and 75 μm pixels were compared to clinical thresholds with 100 μm pixels. Electrical stimulation model calibrated by the clinical and rodent data was used to predict the performance of the implant with smaller pixels. *Main results.* PRIMA implants with 75 μm bipolar pixels under the maximum safe near-infrared (880 nm) illumination of 8 mW mm^{-2} with 30% duty cycle (10 ms pulses at 30 Hz) should provide a similar perceptual brightness as with 100 μm pixels under 3 mW mm^{-2} irradiance, used in the current clinical trials. Contrast of the Landolt C pattern scaled down to 75 μm pixels is also similar under such illumination to that with 100 μm pixels, increasing the maximum acuity from 20/420 to 20/315. *Significance.* Computational modeling defines the minimum pixel size of the PRIMA implants as 75 μm . Increasing the implant width from 2 to 3 mm and reducing the pixel size from 100 to 75 μm will nearly quadruple the number of pixels, which should be very beneficial for patients. Smaller pixels of the same bipolar flat geometry would require excessively intense illumination, and therefore a different pixel design should be considered for further improvement in resolution.

1. Introduction

Retinal degenerative diseases, such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), are the major cause of irreversible visual impairment. RP, a relatively rare class of diseases, originates from various genetic disorders, and typically affects patients in their twenties, eventually leading to profound blindness [1]. Atrophic AMD, on the other hand, causes the loss of central vision later in life due to the gradual demise of photoreceptors, a

condition called geographic atrophy. This form of advanced AMD affects millions of patients: about 3% of people above the age of 75, and around 25% above 90 [2, 3]. Currently, there is no therapy for such scotomata and the loss of sight is permanent.

While photoreceptors degenerate in these diseases, the downstream neurons remain largely intact [4–7]. Electrical stimulation of these neurons allows reintroducing information into the visual pathways for restoration of sight. In RP patients, this approach has been demonstrated with an epiretinal prosthesis

Argus I/II (Second Sight Medical Products, Inc. Sylmar, CA, USA) [8] and with a subretinal prosthesis Alpha IMS/AMS (Retina Implant AG, Reutlingen, Germany), achieving visual acuity up to 20/546 [9, 10]. In AMD patients, subretinal photovoltaic prosthesis PRIMA (Pixium Vision, Paris, France) recently demonstrated its initial safety and efficacy [11, 12]. The PRIMA implant is a photovoltaic array, where each pixel has two photodiodes connected in series between the active electrode in the center and a return electrode on the circumference (figures 1(A) and (B)). The photovoltaic pixels convert images projected from the augmented-reality glasses into patterns of electric current, stimulating the nearby bipolar cells (BCs). The first clinical trial demonstrated a letter acuity closely matching the 100 μm pixel size of the implant (1.17 ± 0.13 pixels), corresponding to the Snellen range of 20/438–20/565 [11, 12]. Furthermore, patients simultaneously perceive prosthetic central vision and natural peripheral vision. This inspiring result indicates that smaller pixels may provide higher resolution to benefit a greater number of patients.

Decreasing the pixel size is not trivial since the retinal stimulation threshold increases nearly quadratically with a decreasing width of bipolar pixels [13], and therefore the lower limit of the pixel size is constrained by the ocular laser safety. For an implant of 3 mm in diameter (the expected dimension in future clinical trials), the steady-state temperature increases by about 2 °C under 5 mW mm⁻² near-infrared (NIR, 880 nm) illumination [14]. To limit the temperature rise by 1 °C (half of the recommended thermal safety limit of 2 °C for active implanted medical devices, according to ISO 14 708-1) with a maximum duty cycle of 30% (10 ms pulses at 30 Hz, for instance), the peak NIR irradiance should not exceed 8.25 mW mm⁻².

Clinical performance of the PRIMA implants with 100 μm pixels demonstrated comfortably bright visual perception under irradiance of 3 mW mm⁻² at the maximum pulse duration of 9.8 ms and repetition rate of 30 Hz [11, 12]. According to the square scaling of the stimulation threshold with a decreasing size of bipolar pixels in rats [13], pixels of 75 μm would require approximately doubling the light intensity, which should still fit within the ocular safety limit. However, since the human retina is thicker and, unlike the RCS rat retina, the inner nuclear layer (INL) is separated from the implant by about 35 μm [11], scaling with the pixel size might be steeper.

In this study, we evaluate the feasibility of the clinical use of 75 μm pixels by relating the implant performance in rats and humans. First, using the electric field model for PRIMA implants, we convert the measured thresholds with 100 μm and 75 μm pixels in rats from the units of irradiance to the voltage step across BCs. Next, using the clinical data with 100 μm pixels and the modeling results, we predict

the corresponding thresholds and maximum stimulus strength with 75 μm pixels in human. Based on benchmarks derived from the successful 100 μm PRIMA implants and their modeling, this approach allows designing and defining the limits of the next-generation retinal prostheses.

2. Methods

All experimental procedures were conducted in accordance with the Statement for the Use of Animals in Ophthalmic and Vision research of the Association for Research in Vision and Ophthalmology (ARVO) and approved by the Stanford Administrative Panel on Laboratory Animal Care. Royal College of Surgeons (RCS) rats were used as an animal model of the inherited retinal degeneration. Animals are maintained at the Stanford Animal Facility under 12 h light/12 h dark cycles with food and water ad libitum.

2.1. Photovoltaic subretinal prosthesis design

To elicit visual perception for restoration of sight, the PRIMA subretinal photovoltaic implants electrically stimulate the second-order retinal neurons, primarily the BCs [15]. Subretinal photovoltaic pixels activated by light [14, 16] act as an optoelectronic substitute for the lost photoreceptors. To reduce the cross-talk between the neighboring pixels, each one has a local return electrode surrounding the active electrode, as illustrated in figure 1(A). Light-to-current conversion in photoreceptors includes a very strong amplification, up to six orders of magnitude: from a few photons per second to pA of current per cell. Since photodiodes do not provide any current amplification and the ambient light intensity is insufficient for electrical stimulation [16], more intense light is required. In addition, capacitive coupling between the electrodes and electrolyte necessitates pulsed charge-balanced stimulation. For these two reasons, the system includes augmented-reality (AR) glasses. Images of the visual scene captured by a video camera are processed and projected by the AR glasses onto a subretinal photodiode array using intense pulsed light. Photovoltaic pixels in the array convert this light into biphasic pulses of electric current, which stimulate the second-order neurons in the INL—primarily the BCs. To avoid perception of this light by the remaining photoreceptors, a near-infrared (NIR, 880 nm) wavelength is used.

This approach offers multiple advantages: (a) thousands of pixels in the implant can be activated simultaneously and independently; (b) since the pixels are activated by light, no wires are involved, which enables reliable encapsulation of the wireless implant and greatly simplifies the surgical procedure; (c) external camera provides autofocusing and adaptation over a wide range of ambient illumination, as well as adjustable image processing optimized for the dynamic range of the implant (the range of stimulus




Figure 1. PRIMA photodiode arrays. (A) A 100 μm pixel array, (B) a 75 μm pixel array. The inset shows the layout of a single pixel, where 1 and 2 are the photosensitive regions of the photodiodes, 3 marks the active electrode, and 4—the circumferential return electrode. (C) A fundus image of an implanted 75 μm pixel array in the temporal-dorsal region of the rat retina. (D) OCT image of the RCS rat retina with a PRIMA implant several weeks post-op. Dashed line indicates the back side of the implant resting on RPE.

strength between the activation threshold and the maximum value supported); (d) the optical nature of the implant maintains the natural link between the eye movements and image perception; (e) network-mediated retinal stimulation retains many features of the natural signal processing, including the antagonistic center-surround [17], flicker fusion at high frequencies and nonlinear summation of the retinal ganglion cell (RGC) subunits [14], among others.

2.2. Surgical procedure and animal handling

The 1.5 mm diameter photovoltaic devices were implanted in the subretinal space of the Retinal College of Surgeons (RCS) rats, typically at 6 months of age, when the outer nuclear layer has degenerated completely. The total loss of the outer nuclear layer was confirmed by the optical coherence tomography (OCT; HRA2-Spectralis; Heidelberg Engineering, Heidelberg, Germany) in each animal prior to surgery. The implants were placed in the temporal-dorsal region, approximately 1 mm away from the optic nerve. The fundus image in figure 1(C) demonstrates the typical location of an implant, and the optical coherence tomography (OCT) in figure 1(D) illustrates the retinal reattachment after surgery. A total of ten animals were implanted with the PRIMA devices consisting of 100 μm ($n = 5$) and 75 μm ($n = 5$) bipolar pixels, as described earlier [18]. Animals were anesthetized with a mixture of ketamine (75 mg kg^{-1}) and xylazine (5 mg kg^{-1}) injected intraperitoneally. To visualize the retina and

the implant, animals were monitored over time using OCT. For measurements of the visually evoked potentials (VEP), each animal was implanted with three transcranial screw electrodes: one electrode over each hemisphere of the visual cortex (4 mm lateral from midline, 6 mm caudal to bregma), and a reference electrode (2 mm right of midline and 2 mm anterior to bregma).

2.3. Electrophysiological measurements

Following anesthesia and pupil dilation, the cornea was covered with a viscoelastic gel and a cover slip to cancel its optical power and maintain good retinal visibility. The implant was illuminated with 880 nm NIR laser (MF-880 nm-400 μm , DILAS, Tucson, AZ) and a digital micromirror display (DMD; DLP Light Commander, LOGIC PD, Carlsbad, CA) was used for a pattern formation. The customized optical system for the pattern projection into the eye was integrated with a slit lamp (Zeiss SL-120; Carl Zeiss, Thornwood, NY) for real-time observation of the retina via a charged-coupled device (CCD) camera (acA1300-60gmNIR; Basler, Ahrensburg, Germany). Light intensity at the cornea was calibrated before and after each measurement session and scaled by the ocular magnification squared to retrieve the irradiance on the implant. Ocular magnification was defined as the ratio between the size of a projected square on the retina and in air.

VEP were recorded across the ipsilateral and contralateral visual cortices via the Espion E3 system




Figure 2. (A) Example VEP waveforms measured in an RCS rat with a 75 μm implant. The top waveform, measured with no NIR stimulus, illustrates the noise, while the middle and bottom traces demonstrate above-threshold waveforms. The arrow indicates the amplitude of the bottom VEP waveform. (B) The peak-to-peak VEP amplitude as a function of irradiance. The arrows point to the first irradiance level yielding an amplitude above the noise band for a given pixel size.

(Diagnosys LLC, Lowell, MA) at a sampling rate of 2 or 4 kHz, averaged over 250 trials. Corneal signal was simultaneously measured across the electroretinogram (ERG) electrodes on the cornea and a reference electrode in the nose. The ground electrode was placed in the rat's tail. The corneal signal served as a template for stimulus artifact removal in the VEP waveforms. The noise floor was extracted from the VEP measurements without illumination. VEP amplitude was measured as the peak-to-peak value in the 150 ms window after the stimuli onset (figure 2(A)).

Stimulation thresholds were measured with full-field and partial-field ($0.65 \times 0.65 \text{ mm}$) illumination (figure 3(C)) with 10 ms pulses at 2 Hz repetition rate and irradiances ranging from 0.024 to 4.7 mW mm^{-2} on the retina. The threshold was defined as the first sampling point where VEP amplitude rises above the noise floor, without any interpolation. To determine the strength-duration relationship of the stimulation threshold, we found the minimum stimulation strength necessary to elicit a significant VEP response at pulse durations ranging from 0.5 to 20 ms.




Figure 3. Example of the VEP amplitude and corneal signal measured with full-field illumination (A), (B) and with a 0.65×0.65 mm square illumination (C), (D).

This range of pulse durations is preferred for selective stimulation of BCs over direct stimulation of RGCs with subretinal anodic pulses [19].

2.4. Electric field modeling

To relate the optical stimuli to the electric potential across BCs, which is considered the figure of merit for the network-mediated retinal stimulation [20], we represented the electric field in the retina by the weighted sum of the pre-computed basis of elementary fields, each of which corresponds to one electrode injecting a unitary current [21]. Such summation is based on linearity of the Poisson's equation describing the volume conduction of electric current in biological tissues. The weights are the current injections of the pixels, calculated from the light pattern on the implant as a function of time, with RPSim, a circuit simulator based on Xyce [22]. Besides the active electrodes, each segment of the return mesh in bipolar pixels array also corresponds to an elementary field, where the nominal ground is set at infinity. Due to conservation of charge on the implant, after superposing the elementary fields from the active and return electrodes, the net current to the infinity is always zero. More details regarding the computational framework for assessing the dynamics of the photovoltaic implants [23] are described in the companion paper [24]. The voltage differences between the somatic and the axonal ends of the BCs govern their stimulus strength [20], and we assume their

average span is from the bottom of the INL to the middle of the inner plexiform layer (IPL), which was about $52 \mu\text{m}$, as measured by OCT.

3. Results

3.1. Electrophysiological performance of PRIMA implants in rodents

To compare the implants' performance in humans and rodents, we examined the electrophysiological response in rats elicited by $100 \mu\text{m}$ PRIMA devices. To better fit the size of the rat eye, implants were 1.5 mm in width instead of the 2 mm ones used in clinical trials [11, 12]. Similar devices with $75 \mu\text{m}$ pixels (figures 1(A) and (B)) were also implanted and evaluated *in-vivo*. Figure 2(A) shows some typical VEP waveforms measured in RCS rats with $75 \mu\text{m}$ pixels at various light intensities. Below the stimulation threshold, the waveforms appear indistinguishable from noise. As NIR (880 nm) light intensity increases, the signature peaks start appearing and grow in amplitude, while retaining the timing. To determine the stimulation threshold, we swept across a wide range of irradiances with 10 ms pulses at 2 Hz repetition rate. Figure 2(B) summarizes the peak-to-peak VEP amplitude as a function of irradiance on the retina. The average stimulation threshold was $0.23 \pm 0.02 \text{ mW mm}^{-2}$ with $100 \mu\text{m}$ pixels, and $0.38 \pm 0.06 \text{ mW mm}^{-2}$ with $75 \mu\text{m}$ pixels. These are conservative estimates, as we take the first points

where VEP amplitudes rise above the noise floor, without extrapolation. Note that the VEP amplitudes at the highest irradiance (5 mW mm^{-2}) [12] with $75 \mu\text{m}$ pixels are similar to those measured at half that irradiance (2.5 mW mm^{-2}) with $100 \mu\text{m}$ pixels. This indicates that perceptual brightness with $75 \mu\text{m}$ pixels under twice higher irradiance might be similar to that with $100 \mu\text{m}$ pixels, which in the current clinical trials produce comfortably bright percepts with irradiance of 3 mW mm^{-2} [11, 12].

The perceptual threshold in human patients was measured using a 16-pixel-wide circular spot (1.6 mm in diameter), with 9.8 ms pulses at 10 Hz repetition rate [12, 25]. In rodents, we apply similar pulse duration and repetition rate, but using full-field illumination to maximize the signal and simplify the alignment. To verify whether full-field and partial-field illumination provide similar thresholds, we measured the VEP also using a local square illumination of $0.65 \times 0.65 \text{ mm}$, as illustrated in figure 3(C). The illuminated local square is approximately half of the total implant area, just as the case in clinical trials. Despite the lower corneal signals with a partial-field illumination (figures 3(D) and (B)), the cortical response amplitude was found to be similar (figures 3(A) and (C)). This indicates some additional signal amplification in the brain, which is not as sensitive to the size of large stimuli on the retina. Therefore, electrophysiological stimulation thresholds derived from full-field illumination may be used for comparison with the perceptual thresholds detected with a large spot illumination.

For further comparison with the clinical results, we also characterized the strength-duration (S-D) relationship of the stimulation threshold with $75 \mu\text{m}$ and $100 \mu\text{m}$ pixels in rats. Figure 4(A) illustrates the stimulation thresholds in terms of light intensity as a function of pulse duration, fitted with the Weiss function for $100 \mu\text{m}$ and $75 \mu\text{m}$ implants. The resulting chronaxie for $100 \mu\text{m}$ pixels was 2.3 ms, in excellent agreement with the chronaxies measured in the PRIMA clinical trial, two examples of which are shown in figure 5(A). Rheobase in the rat measurements (0.17 mW mm^{-2}), however, was significantly lower than even in the best case of human patients (0.4 mW mm^{-2}). This is likely due to the fact that, unlike in RCS rats, INL in human patients is separated from the implant by about $35 \mu\text{m}$ of the debris [12].

3.2. Predictions of clinical performance with $75 \mu\text{m}$ PRIMA implants

BCs are the target neurons in our subretinal approach, and we have shown previously that depolarization of their axonal terminals can be estimated from the voltage step between their top and bottom boundaries [20]. To assess this voltage step, we converted the stimulation thresholds from the irradiance to voltage using the model of electric field generated by photovoltaic arrays in electrolyte [24]. Figure 4(B)

shows the S-D curves for $100 \mu\text{m}$ and $75 \mu\text{m}$ pixels measured in RCS rats, converted into the voltage across BCs, estimated to extend from the bottom of INL (starting about $5 \mu\text{m}$ above the implant) to the middle of IPL, at $57 \mu\text{m}$ height. Despite the very different levels of light intensity shown in figure 4(A), the voltage S-D curves are nearly identical, confirming that the same voltage step is required for BC stimulation, regardless the implant configuration. The rheobases for these two fits are in the range of 8–9 mV, and with 10 ms pulses, the threshold voltage is about 11 mV.

To predict the clinical performance of PRIMA implants with $75 \mu\text{m}$ pixels, we first convert the human stimulation thresholds with $100 \mu\text{m}$ pixels from light intensity into the voltage step across BCs, and then calculate the light intensity required to generate the same voltage with $75 \mu\text{m}$ pixels in human retina. Figure 5(A) shows the lowest and the highest stimulation thresholds in AMD patients reported to date with the $100 \mu\text{m}$ PRIMA implants [12], which we use as the ‘best’ and ‘worst’ cases to estimate the range of responses with future implants. The chronaxie of the S-D relationships are very similar between these two boundary cases (2.2 and 2.3 ms) while the rheobase varies substantially: by a factor of 3.5. Conversion to the corresponding voltage thresholds in human retina, where we assume the INL to begin $35 \mu\text{m}$ above the implant and the middle of IPL at $87 \mu\text{m}$, based on clinical OCT images [12], is shown in figure 5(B). For the worst case, a rheobase is about 16.4 mV, roughly twice the rheobase measured in rodents, which may be due to the reduced neural excitability in the badly degenerated retina. In the best case, the stimulation thresholds are more than three times lower, with a corresponding rheobase of 4.7 mV. This value is below the approximate turn-on voltage of the Ca ion channels ($>8 \text{ mV}$) [26, 27]. This discrepancy could be reconciled if we assume that dendrites of the BCs in the best-case patient extend below the cell soma, thereby reducing the distance from the implant. If we assume that the BC stimulation threshold in human retina in the best-case scenario is similar to that in rats, the distance between the dendrites and the implant surface should be about $20 \mu\text{m}$. This S-D curve, also shown in figure 5(B), lies in between the best and the worst cases, with a rheobase of 9.7 mV.

Given the voltage step across BCs, we can now calculate the light intensity required for generating such a voltage drop with $75 \mu\text{m}$ pixel arrays in human retina. Figure 5(C) shows the predicted stimulation thresholds in units of irradiance as a function of pulse duration for the two boundary cases. For the worst-case scenario, the rheobase is 3.5 mW mm^{-2} –2.5 times higher than in the worst case with $100 \mu\text{m}$ pixels. This increase closely matches the 2.59 ratio of the photosensitive area in 100 and $75 \mu\text{m}$ PRIMA pixels: $4075 \mu\text{m}^2$ vs. $1576 \mu\text{m}^2$, respectively. This




Figure 4. (A) The irradiance thresholds as a function of pulse duration measured in RCS rats with 100 μm and 75 μm pixel arrays. The solid and dashed lines show the fitted strength-duration curves according to Weiss equation. (B) The converted strength-duration curves in units of voltage across bipolar cells in rat retina.

similarity indicates that the same current per pixel is required to produce the same voltage drop across the BCs with these two arrays. This, in turn, indicates that higher current density per unit area of the implant with smaller pixels is compensated by stronger field confinement with denser return electrodes grid. With the irradiance of 8 mW mm^{-2} , stimulation should exceed the worst-case threshold with pulses longer than 2.6 ms, which is similar to the minimum pulse duration with 100 μm pixels under 3 mW mm^{-2} used in the clinical trial [12].

For the best-case scenario, required irradiance can be predicted two ways. First, using a ‘naive’ voltage threshold, which assumes the BCs residing 35 μm above the implant and having the rheobase of 4.7 mV. The more physiologically realistic voltage thresholds,

as described above, correspond to BCs extending their dendrites down to 20 μm above the implant and having the rheobase of 9.7 mV. Interestingly, both models yield very similar S-D curves in units of light intensity, as shown in figure 5(C). Here again, the ratio of the average rheobase with 75 μm pixels (1.05 mW mm^{-2}) to that with 100 μm pixels shown in figure 5(A) (0.4 mW mm^{-2}) is about 2.6, like in the worst-case scenario. Therefore, clinical performance of the 75 μm implants in the best and the worst cases under 8 mW mm^{-2} irradiance should be similar to that in the clinical trial with 100 μm pixels, where irradiance was about 2.6 times lower— 3 mW mm^{-2} [11, 12].

Prosthetic visual acuity is fundamentally limited by the pixel pitch. We have demonstrated that




Figure 5. Strength-duration (S-D) relationships for human thresholds with 100 and 75 μm pixel arrays. (A) Perceptual thresholds for the best and worst cases measured with 100 μm PRIMA implants. (B) Stimulation thresholds in terms of a voltage drop across bipolar cells (BCs) for the best and the worst case, converted from A. The middle line represents the best-case thresholds with 100 μm implants adjusted to 20 μm separation between the BCs and the implant to match the rodent data (from figure 4(B)). (C) The predicted S-D curves for 75 μm pixels in all three cases, converted from voltage to irradiance.

prosthetic visual acuity matches the pixel pitch of our subretinal implants with pixel size of 75 [14], 55 [28], and 40 [29] μm in rodents, and of 100 μm in patients [11]. In clinical trials, acuity was assessed using the Landolt C optotype, projected with 9.8 ms pulses at 30 Hz. Theoretically, the minimum resolvable font size corresponds to the gap of 1 pixel in the letter C. Patients resolved the fonts in the range of 1.04–1.3 pixels per gap, with the average of 1.17 pixels [12]. To check the expected resolution with 75 μm pixels, we calculated the electric potential across BCs when a Landolt C font with a gap of 1.2 pixel (90 μm) was projected onto the photovoltaic array with the irradiance of 8 mW mm^{-2} and 9.8 ms pulses at 30 Hz (figure 6). As with the stimulation thresholds, we calculated the field maps for two scenarios: if the BCs are separated from the implant by 35 μm and by 20 μm . With the 35 μm separation, we outlined two thresholds for 10 ms pulses: for the best (5.6 mV) and the worst (18.9 mV) cases. For the 20 μm separation, assumed only for the best case, the threshold is 11.8 mV. As shown in figures 6(B) and (C), the predicted contours of visibility for the best case in two scenarios are very similar. The worst case, as shown in figure 6(B), represents a much narrower letter with a wavy outline. However, with the eye movements, this wavy structure may average out and hence not be noticeable by the patients. Amplitude of the electric


potential in these maps (57 mV for 20 μm and 28 mV for 35 μm height) is very close to that calculated for the 100 μm pixels under 3 mW mm^{-2} irradiance: 62 mV and 31 mV, respectively [24].

Under 3 mW mm^{-2} illumination of the 75 μm pixels, the voltage steps across BCs are expectedly lower: 23 mV for 20 μm and 11 mV for 35 μm separation between the implant and BCs, respectively. For the worst case, such voltage drop is even below the stimulation threshold, so, clearly, much higher irradiance is required with 75 μm pixels.

Under 8 mW mm^{-2} irradiance with 75 μm pixels, the 1.2 pixel gap in Landolt C is expected to have a similar perceptual brightness and contrast of the pattern as in the current clinical trials, and hence should be resolvable. If resolution of prosthetic vision will not be limited by other factors in patients, this would improve the average visual acuity from 20/500 to 20/380.

4. Discussion

The predicted stimulation thresholds with 75 μm bipolar pixels are higher than those measured with 100 μm pixels by a factor of about 2.5, approximately matching the ratio of the photosensitive areas in these pixels. This means that the same current per pixel is required for stimulation, as would be with the



electric field of a point source. Such a simple approximation is expected with stimulating electrodes smaller than the distance to the target cells and with a return electrode located much further away than the target cells. However, with the BCs extending over more than 50 μm , this is not the case even with RCS rat retina, where INL begins within a few micrometers from the implant. Even less so in AMD patients, where INL is separated from the implant by about 35 μm [12]. In our case, neurons are separated from the active electrodes and the mesh of circumferential return electrodes in each pixel by distances comparable to the pixel size. In this case, decreasing pixel size in a pattern activation has two counteracting effects: (a) higher current density per unit area generated with smaller pixels injecting the same current per electrode should increase the electric potential, but at the same time, (b) the electric field is diminished by the denser mesh of the return electrodes in the array. These two effects counteract each other, resulting in

the threshold scaling according to the constant electric current per pixel in our geometry.

Perceptual brightness and contrast of the patterns with 75 μm pixels at 8 mW mm^{-2} is expected to be similar to that with 100 μm pixels at 3 mW mm^{-2} irradiance in humans. Since 8 mW mm^{-2} with a 30% duty cycle is close to the NIR retinal safety limit, further reduction in pixel size of the same geometry is unlikely. In rodents, where INL is closer to the implant, we demonstrated a prosthetic visual acuity matching the pixel pitch even with 55 μm bipolar pixels [28], but for human retina, such pixel size would require light intensity exceeding the safety limits.

Bipolar pixels effectively prevent the cross-talk between neighboring pixels, but they do it by overly constraining the electric field. Placing a local return electrode inside each pixel creates a dark ring between the adjacent bright spots in the pattern. Ideally, the electric field should be confined such that the bright

pixel creates a stimulation spot, while the dark pixel does not, without a dark boundary around the active pixels. This can be achieved using current steering, if the active electrodes on monopolar pixels could be used for both, injecting and collecting the current, i.e. as the active and return electrodes [18, 21]. Additionally, 3-dimensional electrodes can improve the electric field penetration into the tissue, thereby maintaining a low stimulation threshold and good contrast, such as the honeycomb and pillar layouts [13, 30].

5. Conclusions

Under the maximum safe NIR irradiance (8 mW mm^{-2} with 30% duty cycle), the $75 \mu\text{m}$ PRIMA implants should provide a similar perceptual brightness to that with the $100 \mu\text{m}$ pixels under 3 mW mm^{-2} , which is used in the first clinical trials. It should also maintain sufficient contrast for resolving a Landolt C with a gap width of 1.2 pixel, corresponding to the visual acuity of 20/380. A decrease in the pixel size from 100 to $75 \mu\text{m}$ and an increase in the implant width from 2 to 3 mm will nearly quadruple the number of pixels in an implant, which would be beneficial for AMD patients. Further decrease of the pixel size in flat bipolar geometry would require exceedingly bright illumination, and therefore a different electrode geometry should be considered for further improvement in resolution.

Data availability statement

The data that support the findings of this study are available upon reasonable request from the authors.

Acknowledgments

The authors wish to thank Pixium Vision for providing the PRIMA implants with $100 \mu\text{m}$ and $75 \mu\text{m}$ pixels. The financial support was provided in part by the National Institutes of Health (Grants R01-EY-027786 and P30-EY-026877), the Department of Defense (Grant W81XWH-19-1-0738), AFOSR (Grant FA9550-19-1-0402), Wu Tsai Institute of Neurosciences at Stanford, and an unrestricted grant from Research to Prevent Blindness.

ORCID iDs

Bing-Yi Wang  <https://orcid.org/0000-0001-8336-3285>

Zhijie Charles Chen  <https://orcid.org/0000-0003-2705-065X>

Mohajeet Bhuckory  <https://orcid.org/0000-0002-2824-1899>

Anna Kochnev Goldstein  <https://orcid.org/0000-0003-4674-688X>

Daniel Palanker  <https://orcid.org/0000-0002-0480-3025>

References

- [1] Haim M 2002 Epidemiology of retinitis pigmentosa in Denmark *Acta Ophthalmol. Scand. Suppl.* **80** 1–34
- [2] Friedman D S, O'Colmain B J, Muñoz B, Tomany S C, McCarty C, de Jong P T V M, Nemesure B, Mitchell P and Kempen J Eye Diseases Prevalence Research Group 2004 Prevalence of age-related macular degeneration in the United States *Arch. Ophthalmol.* **122** 564–72
- [3] Wong W L, Su X, Li X, Cheung C M G, Klein R, Cheng C-Y and Wong T Y 2014 Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis *Lancet Glob. Health* **2** e106–16
- [4] Santos A, Humayun M S, de Juan E Jr, Greenburg R J, Marsh M J, Klock I B and Milam A H 1997 Preservation of the inner retina in retinitis pigmentosa: a morphometric analysis *Arch. Ophthalmol.* **115** 511–5
- [5] Kim S Y, Sadda S, Humayun M S, de Juan E, Melia B M and Green W R 2002 Morphometric analysis of the macula in eyes with geographic atrophy due to age-related macular degeneration *Retina* **22** 464–70
- [6] Stone J L, Barlow W E, Humayun M S, de Juan E and Milam A H 1992 Morphometric analysis of macular photoreceptors and ganglion cells in retinas with retinitis pigmentosa *Arch. Ophthalmol.* **110** 1634–9
- [7] Humayun M S, Prince M, de Juan E, Barron Y, Moskowitz M, Klock I B and Milam A H 1999 Morphometric analysis of the extramacular retina from postmortem eyes with retinitis pigmentosa *Invest. Ophthalmol. Vis. Sci.* **40** 143–8
- [8] Ho A C *et al* Argus II Study Group 2015 Long-term results from an epiretinal prosthesis to restore sight to the blind *Ophthalmology* **122** 1547–54
- [9] Stingl K *et al* 2015 Subretinal visual implant alpha IMS—clinical trial interim report *Vis. Res.* **111** 149–60
- [10] Stingl K *et al* 2017 Interim results of a multicenter trial with the new electronic subretinal implant alpha AMS in 15 patients blind from inherited retinal degenerations *Front. Neurosci.* **11** 445
- [11] Palanker D, Le Mer Y, Mohand-Said S and Sahel J A 2022 Simultaneous perception of prosthetic and natural vision in AMD patients *Nat. Commun.* **13** 513
- [12] Palanker D, Le Mer Y, Mohand-Said S, Muqit M and Sahel J A 2020 Photovoltaic restoration of central vision in atrophic age-related macular degeneration *Ophthalmology* **127** 1097–104
- [13] Flores T, Huang T, Bhuckory M, Ho E, Chen Z, Dalal R, Galambos L, Kamins T, Mathieson K and Palanker D 2019 Honeycomb-shaped electro-neural interface enables cellular-scale pixels in subretinal prosthesis *Sci. Rep.* **9** 10657
- [14] Lorach H *et al* 2015 Photovoltaic restoration of sight with high visual acuity *Nat. Med.* **21** 476–82
- [15] Cehajic Kapetanovic J, Troelenberg N, Edwards T L, Xue K, Ramsden J D, Stett A, Zrenner E and MacLaren R E 2020 Highest reported visual acuity after electronic retinal implantation *Acta Ophthalmol.* **98** 736–40
- [16] Mathieson K *et al* 2012 Photovoltaic retinal prosthesis with high pixel density *Nat. Photon.* **6** 391–7
- [17] Ho E, Smith R, Goetz G, Lei X, Galambos L, Kamins T I, Harris J, Mathieson K, Palanker D and Sher A 2018 Spatiotemporal characteristics of retinal response to network-mediated photovoltaic stimulation *J. Neurophysiol.* **119** 389–400
- [18] Huang T W *et al* 2021 Vertical-junction photodiodes for smaller pixels in retinal prostheses *J. Neural Eng.* **18** 036015
- [19] Boinagrov D, Pangratz-Fuehrer S, Goetz G and Palanker D 2014 Selectivity of direct and network-mediated stimulation of the retinal ganglion cells with epi-, sub- and intraretinal electrodes *J. Neural Eng.* **11** 026008

- [20] Werginz P, Wang B-Y, Chen Z C and Palanker D 2020 On optimal coupling of the ‘electronic photoreceptors’ into the degenerate retina *J. Neural Eng.* **17** 045008
- [21] Chen Z C, Wang B-Y and Palanker D 2021 Real-time optimization of the current steering for visual prosthesis 2021 *10th Int. IEEE/EMBS Conf. on Neural Engineering (NER)* (Italy: IEEE) pp 592–6
- [22] Keiter E, Aadithya K, Mei T, Thornquist H, Sholander P and Wilcox I 2019 *Xyce Parallel Electronic Simulator Users’ Guide Version 7.5* (Albuquerque, NM: Sandia National Laboratories) (available at: www.osti.gov/biblio/1866027)
- [23] Chen C Z, Kochnev Goldstein A and Palanker D 2022 PalankerLab/RPSim: RPSim v1.0.0 *Zenodo* (<https://doi.org/10.5281/zenodo.6774591>)
- [24] Chen Z C, Wang B, Goldstein A K, Butt E, Mathieson K and Palanker D 2022 Photovoltaic implant simulator reveals the resolution limits in subretinal prosthesis *J. Neural Eng.* (<https://doi.org/10.1101/2022.06.30.498210>)
- [25] Lieberman H R and Pentland A P 1982 Microcomputer-based estimation of psychophysical thresholds: the best PEST *Behav. Res. Methods Instrum.* **14** 21–25
- [26] Werginz P, Benav H, Zrenner E and Rattay F 2015 Modeling the response of ON and OFF retinal bipolar cells during electric stimulation *Vis. Res.* **111** 170–81
- [27] Protti D A and Llano I 1998 Calcium currents and calcium signaling in rod bipolar cells of rat retinal slices *J. Neurosci.* **18** 3715–24
- [28] Ho E, Lei X, Flores T, Lorach H, Huang T, Galambos L, Kamins T, Harris J, Mathieson K and Palanker D 2019 Characteristics of prosthetic vision in rats with subretinal flat and pillar electrode arrays *J. Neural Eng.* **16** 066027
- [29] Wang B-Y *et al* 2021 Electronic “photoreceptors” enable prosthetic vision with acuity matching the natural resolution in rats *bioRxiv Preprint* (posted online 22 July 2021, accessed 23 April 2022)
- [30] Flores T, Lei X, Huang T, Lorach H, Dalal R, Galambos L, Kamins T, Mathieson K and Palanker D 2018 Optimization of pillar electrodes in subretinal prosthesis for enhanced proximity to target neurons *J. Neural Eng.* **15** 036011